Catalyst Pharmaceuticals, Inc.

Please note: The information displayed on this page might be outdated.
Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst's New Drug Application for FIRDAPSEĀ® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - South Atlantic
Clinical Stage
Phase III, Phase l or ll
Disease Space
Rare Disease
Finance
Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
500MM - 1B
Therapeutic Modalities
Small Molecule
Website:
Profiles:
Address:
355 Alhambra Circle
Suite 801
Coral Gables, FL 33134
United States

Company Participants at Solebury Trout 1x1 Management Access Event 2022

  • Jeff Del Carmen, CCO
  • Mary Coleman, Vice President, Investor Relations
  • Patrick J McEnany, Chairman/President/CEO/Co-Founder
  • Steven Miller, Chief Operating Officer & Chief Scientific Officer

Top 10 Holders of Catalyst Pharmaceuticals, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Armistice Capital LLC 8.15 8,372,000 59.11 13F 3/31/22
SSgA Funds Management, Inc. 4.90 5,050,989 35.66 Stakes 12/31/21
The Vanguard Group, Inc. 4.69 4,836,313 34.14 Stakes 12/31/21
State Street Corp. 4.49 4,617,955 32.60 13F 3/31/22
Vanguard Group, Inc. (Subfiler) 4.47 4,588,303 32.39 13F 3/31/22
BlackRock Fund Advisors 3.73 3,835,389 27.08 13F 3/31/22
LSV Asset Management 3.60 3,703,272 26.15 13F 3/31/22
Royce & Associates LP 2.20 2,261,907 15.97 13F 3/31/22
BlackRock Institutional Trust Co. NA 2.17 2,228,285 15.73 13F 3/31/22
Dimensional Fund Advisors LP 2.09 2,145,254 15.15 13F 3/31/22
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.